P1, N=29, Terminated, Deciphera Pharmaceuticals, LLC | Phase classification: P1/2 --> P1 | N=140 --> 29 | Trial completion date: Aug 2027 --> Feb 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Feb 2026; Trial terminated due to a business decision, not based on any safety concerns.

25 days ago

Phase classification • Enrollment change • Trial completion date • Trial termination • Trial primary completion date

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • NF1 (Neurofibromin 1) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)

BRAF mutation

DCC-3084

2ms

A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=60, Recruiting, Beijing StoneWise Technology Co., Ltd

2 months ago

New P1 trial • First-in-human

3ms

Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axis. (PubMed, Anticancer Drugs)

In-vivo studies demonstrated a reduced leukemia burden in xenograft models. This study is the first to elucidate that BGB-15025 triggers AML apoptosis through cell cycle blockade and MAPK pathway inhibition, thereby proposing a novel precision therapeutic strategy with significant clinical translational value.

3 months ago

Journal

CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)

BGB-15025

3ms

BGB-A317-15025-101: BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=157, Active, not recruiting, BeiGene | Trial completion date: Oct 2026 --> May 2026

3 months ago

Trial completion date

Tevimbra (tislelizumab-jsgr) • BGB-15025

3ms

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=39, Active, not recruiting, Zhuhai Yufan Biotechnologies Co., Ltd | Trial completion date: Oct 2024 --> Jun 2026 | Completed --> Active, not recruiting

3 months ago

Enrollment closed • Trial completion date • First-in-human

4ms

A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=42, Active, not recruiting, Broadenbio Ltd., Co. | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2025 --> May 2025

4 months ago

Enrollment closed • Trial primary completion date

6ms

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) (clinicaltrials.gov)

P2, N=79, Not yet recruiting, Nationwide Children's Hospital

6 months ago

New P2 trial

BRAF (B-raf proto-oncogene)

Ojemda (tovorafenib)

6ms

DCC-3084-01-001: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (clinicaltrials.gov)

P1/2, N=140, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Recruiting --> Active, not recruiting

6 months ago

Enrollment closed

DCC-3084

6ms

Targeting JNK1/2 and P38 Mitogen-Activated Protein Kinases With Pazopanib Mitigates Bleomycin-Induced Lung Fibrosis. (PubMed, Arch Pharm (Weinheim))

Remarkably, pazopanib treatment reversed the bleomycin-induced elevation in transforming growth factor-beta-1 (TGF-β1) and α-smooth muscle actin (α-SMA) levels. Our research highlighted the beneficial role of pazopanib in attenuating bleomycin-elicited lung fibrosis through the suppression of MEKK2 and MEKK3 and the modulation of JNK and P38 cascades.

6 months ago

Journal

MAP2K2 (Mitogen-activated protein kinase kinase 2) • TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • IL13 (Interleukin 13) • IL33 (Interleukin 33) • MAPK8 (Mitogen-activated protein kinase 8)

pazopanib • bleomycin

6ms

Jingui Shenqi pill ( ) treats cardiorenal syndrome by inhibiting mitogen-activated protein kinase signaling pathway and reducing inflammatory response. (PubMed, J Tradit Chin Med)

Jingui Shenqi pill can exert therapeutic effects on cardiorenal syndrome by inhibiting the activation of the MAPK signaling pathway and inflammatory responses.

6 months ago

Journal

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)

doxorubicin hydrochloride

6ms

The Impact of Proinflammatory M1 Macrophages on the Proliferation and Expression of Cyclin E2, Mitogen-Activated Protein Kinases 4 and 7 in Hepatocytes Isolated from a Diethylnitrosamine-Induced Hepatocellular Carcinoma Rat Model. (PubMed, Molecules)

(4) Our findings indicate that CE2 expression is upregulated in PH/DEN cells, with a notable decrease in the presence of M1 macrophages. In contrast, compared with control macrophages, M1 macrophages did not significantly affect Mapk4/7 expression.

6 months ago

Preclinical • Journal • IO biomarker

CCNE2 (Cyclin E2) • MAPK4 (Mitogen-Activated Protein Kinase 4)